Craft
  • Home
  •  / Nipro Corporation
Nipro Corporation

Nipro Corporation

Syrups Produced, bottles

460 K

Y, 2020

Revenue

¥442.5 B

FY, 2020

Market Capitalization

¥177 B

2022-09-21

Nipro Corporation Summary

Company summary

Overview
Nipro Corporation (ニプロ株式会社) is a company that develops medical devices, pharmaceuticals, and pharma packaging. It offers various disposable medical products comprising renal, intervention and anesthesiology, injection and infusion, dialysis, cardiopulmonary, diabetic, and cell culture products. The company also provides double bags, pre-filled syringes, half-type kits, glass molding vials, ampoules, cartridges, and other solutions.
Type
Public
Founded
1954
HQ
Osaka, JP | view all locations
Website
https://www.nipro.co.jp/en/corporate/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Sano Yoshihiko

    Sano Yoshihiko, President

    • Yoshioka Kiyotaka, Managing Director

      • Masuda Toshiaki, Managing Director

        • Kobayashi Kyoetsu, Managing Director

          Operating MetricsView all

          Pre-filled Syringes Produced

          160M

          Y, 2020

          Poultices Produced, 10g-sheets

          390M

          Y, 2020

          Tapes Produced (Hotmelt Type), sheets

          580M

          Y, 2020

          LocationsView all

          5 locations detected

          • Osaka, Osaka HQ

            Japan

            3-chōme-9-3 Honjōnishi, Kita-ku

          • Bunkyo City, Tōkyō-to

            Japan

            4-chōme-3-4 Hongō

          • Kusatsu, Shiga

            Japan

            3023 Nojicho

          • Kusatsu, Shiga

            Japan

            61 - 9 Sasatani, Yamadera - cho

          • Ohdate, Akita

            Japan

            8-7 Hanukiyachi, Niida

          Nipro Corporation Financials

          Summary financials

          Revenue (Q3, 2021)
          ¥341.1B
          Gross profit (Q3, 2021)
          ¥105.3B
          Net income (Q3, 2021)
          ¥10.9B
          Cash (Q3, 2021)
          ¥106.0B
          EBIT (Q3, 2021)
          ¥23.1B
          Enterprise value
          $621.1B

          Footer menu